<DOC>
	<DOCNO>NCT03025360</DOCNO>
	<brief_summary>Larotrectinib ( LOXO-101 ) expand access patient cancer NTRK1 , NTRK2 , NTRK3 gene fusion ineligible ongoing larotrectinib ( LOXO-101 ) clinical trial consideration prevent access larotrectinib ( LOXO-101 ) exist clinical trial . Expanded access intend treat individual patient different type cancer NTRK gene fusion .</brief_summary>
	<brief_title>Expanded Access Provide Larotrectinib ( LOXO-101 ) Treatment Cancers With NTRK Gene Fusion</brief_title>
	<detailed_description />
	<criteria>Diagnosis cancer NTRK1 , NTRK2 , NTRK3 gene fusion Are unable participate ongoing larotrectinib ( LOXO101 ) clinical trial Willing able provide write , sign informed consent Medically suitable treatment larotrectinib ( LOXO101 ) Currently enrol ongoing clinical study larotrectinib ( LOXO101 ) another TRK inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>